297 results on '"Daizadeh, Nadia"'
Search Results
2. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
3. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
4. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.
5. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
6. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
7. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype
8. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline
9. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
10. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
11. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
12. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
13. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
14. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
15. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
16. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
17. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
18. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
19. Decentralized clinical trials: scientific considerations through the lens of the estimand framework
20. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
21. Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma
22. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
23. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
24. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
25. Dupilumab long-term efficacy in patients with non–OCS–dependent asthma with and without evidence of allergic asthma.
26. Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study
27. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
28. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
29. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
30. Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
31. Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1
32. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials
33. Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
34. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma.
35. Efficacy of Dupilumab in the Prevention of Seasonal Exacerbations in Patients With and Without Evidence of an Allergic Asthma Phenotype
36. Dupilumab Efficacy in LIBERTY ASTHMA QUEST Patients With Uncontrolled, Moderate-to-Severe Asthma By Allergen Sensitization Status
37. Dupilumab in CRSwNP : Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
38. LONG-TERM EFFECT OF DUPILUMAB ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 ASTHMA: LIBERTY ASTHMA TRAVERSE STUDY
39. LONG-TERM EFFICACY OF DUPILUMAB IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA: LIBERTY ASTHMA TRAVERSE
40. 166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE
41. DUPILUMAB REDUCED ORAL CORTICOSTEROID USE AND IMPROVED CLINICAL OUTCOMES REGARDLESS OF BASELINE OCS DOSE IN PATIENTS WITH UNCONTROLLED, SEVERE ASTHMA IN THE LIBERTY ASTHMA VENTURE STUDY
42. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
43. Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST
44. Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE
45. Effect of dupilumab on improving physical activity in patients with severe asthma
46. Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients
47. Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
48. Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
49. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
50. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.